CTLA4 and cancer: Cancer immunotherapies that target the immunosuppressive checkpoint receptors cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) or programmed death 1 (PD-1) and its ligand, programmed death 1 ligand (PD-L1), have changed the landscape of cancer treatment [2].